

Table of Contents

Table of Contents

Table of Contents.....	ii
List of Figures.....	vi
List of Table.....	x
List of abbreviations.....	xii
Abstract	xvii
1. Introduction.....	1
1.1 Epidemiology	1
1.2 HCC therapeutics.....	2
1.2.1 Curative treatments.....	2
1.2.2 Locoregional treatments	2
1.2.3 Systemic chemotherapy	4
1.3 Medicinal plants with anticancer activity	4
1.4 Rationale	5
1.4.1 <i>Achyrathes aspera</i>	7
1.4.2 <i>Boerhaavia diffusa</i>	9
1.4.3 <i>Enicostemma littorale</i>	11
1.5 Aim/ Objectives:.....	14
2. Review of literature.....	15
2.1 Causative agent of HCC and their molecular mechanisms.....	16
2.1.1 HBV.....	16
2.1.2 HCV.....	17
2.1.3 Alcohol	17
2.1.4 Non-alcoholic steatohepatitis (NASH).....	17
2.2 HCC in India	18
2.3 Pathophysiology of hepatocellular carcinoma	18

Table of Contents

2.4 Classification of HCC	24
2.5 Diagnosis and disease marker of HCC	27
2.5.1 Alfa-fetoprotein (AFP)	29
2.5.2 Vascular endothelial growth factor (VEGF).....	29
2.5.3 Des-gamma-carboxy prothrombin (DCP)	29
2.5.4 Dickkopf-1 (DKK1)	29
2.5.5 Golgi protein 73 (GP73).....	30
2.5.6 Glypican-3 (GPC3).....	30
2.5.7 Angiography	30
2.5.8 Liver biopsy	30
2.6 HepG2 cell line.....	30
2.7 Treatment of HCC	30
2.8 Prevention of HCC by vaccination.....	33
2.9 Animal models for screening of anti-cancer drugs.....	34
2.9.1 Chemically induced models.....	34
2.9.2. Cell-derived xenograft (CDX) model.....	38
2.9.3. Viral models for HCC.....	39
2.9.4. Genetically engineered mouse (GEM) model.....	39
2.10 Plant profile	40
2.10.1 <i>Achyranthus aspera</i>	40
2.10.2 <i>Boerhaavia diffusa</i>	45
2.10.3 <i>Enicostemma littorale</i>	49
3. Material and method.....	53
3.1 Chemicals and Reagents	53
3.2 Animals	53
3.3 Collection of plant materials	54

Table of Contents

3.4 Herbarium preparation and plant identification	54
3.5 Extraction of plant material.....	55
3.6 Phytochemical screening.....	55
3.7 Phytochemical analysis by LCMS.....	55
3.8 Molecular docking	56
3.9 Cell culture	57
3.10 In-vitro assay	58
3.10.1 MTT cell viability assay	58
3.10.2 Wound healing assay (Scratch motility assay)	59
3.10.3 Colony formation assay	60
3.10.4 Assay of apoptosis (Annexin V FITC/PI Assay)	61
3.11 Evaluation of the extract in in-vivo animal model	62
3.11.1 Evaluation of the extracts for safety by acute toxicity study	62
3.11.2 Development and standardization of chemically induced animal model for HCC62	
3.11.3 Development of tumor model with HepG2 cells in nude mice	66
3.12 Statistical analysis.....	75
4. Results	76
4.1 Extraction of plant material.....	76
4.2 MTT (cytotoxicity) assay	82
4.3 Scratch motility (wound healing) assay.....	86
4.4 Colony formation (clonogenic cell survival) assay	88
4.5 Apoptosis assay	90
4.6 Phytochemical analysis of extracts by LCMS.....	91
4.7 Molecular Docking	104
4.8 Acute toxicity study as per OECD guideline 423	128
4.9 DEN and 2-AAF induced HCC in rats	130

Table of Contents

4.10 DEN and CCl ₄ induced HCC in rats.....	133
4.11 Subcutaneous xenograft model.....	139
4.11.1 Growth pattern of HepG2 cells in male and female mice	139
4.11.2 Standardization of xenograft model with different cell number.....	140
4.11.3 Efficacy study of extracts in xenograft model with different cell number.....	141
4.11.4 Evaluation of efficacy of extracts alone and in combination with sorafenib in tumor bearing mice	145
5. Discussion.....	168
6. Conclusion.....	179
7. References.....	180
8. Annexure	204
8.1 Herbarium Certificate.....	204
8.2 Certificate of analysis for alcoholic extract of <i>A. aspera</i>	205
8.3 Certificate of analysis for alcoholic extract of <i>B. diffusa</i>	207
8.4 Certificate of analysis for alcoholic extract of <i>E. littorale</i>	208
8.5 IAEC approval	209
8.6 Published paper (JNR).....	210
9. Publications and Presentations.....	211
9.1 Publications/book chapter.....	211
9.2 Oral presentations	211
9.3 Conferences/ Seminar/Workshop attended.....	211

Table of Contents

List of Figures

Figure 1.1: Network pharmacology diagram for <i>A. aspera</i>	9
Figure 1.2: Network pharmacology diagram for <i>B. diffusa</i>	11
Figure 1.3: Network pharmacology diagram for <i>E.littorale</i>	13
Figure 2.1: Causative agents of HCC.....	16
Figure 2.2: Major signaling pathways involved in HCC	20
Figure 2.3: Genetic alteration in hepatocellular carcinoma	23
Figure 2.4: BCLC staging system and treatment strategy for HCC	26
Figure 2.5: Development of HCC and first-line treatment options for each stage	33
Figure 2.6: HCC treatment option with their mechanism of action.....	33
Figure 2.7: <i>A. aspera</i> plant and root.....	40
Figure 2.8: <i>B. diffusa</i> plant and root.....	45
Figure 2.9: <i>E. littorale</i> plant	49
Figure 3.1: Flow chart for selection of extract for in-vitro and in-vivo study based on MTT assay	58
Figure 3.2: Mechanism for conversion of MTT to formazan.....	59
Figure 3.3: Systematic diagram for DEN and 2-AAF induced HCC model in rats	64
Figure 3.4: Systematic diagram for DEN and CCl ₄ induced HCC model in rats.....	65
Figure 3.5: Systematic diagram for cell injection and tumor staging	67
Figure 3.6: Systematic diagram for cell injection, dosing & efficacy study of extracts.....	69
Figure 3.7: Systematic diagram for cell injection, dosing & efficacy study of extract and sorafenib combination.....	71
Figure 4.1: Percentage cell viability with <i>A. aspera</i> extracts in MTT assay.....	82
Figure 4.2: Percentage cell viability with <i>B. diffusa</i> extracts in MTT assay.....	83
Figure 4.3: Percentage cell viability with <i>E. littorale</i> extracts in MTT assay.....	84
Figure 4.4: Percentage cell viability with sorafenib in MTT assay	85

Table of Contents

Figure 4.5: Graphical abstract of results obtained by MTT assay	86
Figure 4.6: Percentage wound healing with <i>A. aspera</i> , <i>B. diffusa</i> extracts and sorafenib on the HepG2 cells scratch motility assay	87
Figure 4.7: Inhibitory effects of <i>A. aspera</i> , <i>B. diffusa</i> extracts and sorafenib on the migration of HepG2 cells	88
Figure 4.8: Percentage colony formation assay following treatment with <i>A. aspera</i> , <i>B. diffusa</i> extracts and sorafenib on HepG2 cells.....	89
Figure 4.9: Colony formation following treatment with <i>A. aspera</i> , <i>B. diffusa</i> extracts and sorafenib on HepG2 cells colony formation assay	89
Figure 4.10: The alcoholic extract of <i>A. aspera</i> and <i>B. diffusa</i> induced early and late stage apoptosis in the HepG2 cell line	91
Figure 4.11: LCMS chromatogram of alcoholic extract of <i>A. aspera</i> (ES+ ve)	93
Figure 4.12: LCMS chromatogram of alcoholic extract of <i>A. aspera</i> (ES- ve)	93
Figure 4.13: Mass spectrum and structure of phytoconstituents detected by LCMS in alcoholic <i>A. aspera</i> extract	94
Figure 4.14: LCMS chromatogram of alcoholic extract of <i>B. diffusa</i> (ES+ve)	99
Figure 4.15: LCMS chromatogram of alcoholic extract of <i>B. diffusa</i> (ES-ve)	99
Figure 4.16: Mass spectrum and structure of phytoconstituents detected by LCMS in alcoholic <i>B. diffusa</i> extract	100
Figure 4.17: Body weight in DEN and 2-AAF induced HCC model	132
Figure 4.18: Photomicrographs of liver sections of normal and DEN with 2-AAF administered rats	133
Figure 4.19: Body weight in DEN and CCl ₄ induced HCC model.....	138
Figure 4.20: Photomicrographs of liver sections of normal, DEN with CCl ₄ (single dose) and DEN with CCl ₄ (three dose) administered in rats.....	139
Figure 4.21: HepG2 cell growth pattern in male and female mice.....	140
Figure 4.22: Growth pattern of HepG2 cells inoculation with different cell number per mouse	141

Table of Contents

Figure 4.23: Efficacy of extracts in female mice (0.5 million cells/animal).....	143
Figure 4.24: Efficacy of extracts in female mice (1 million cells/animal).....	144
Figure 4.25: Efficacy of extracts in female mice (5 million cells/animal).....	145
Figure 4.26: Efficacy of <i>A. aspera</i> in HepG2 CDX model	147
Figure 4.27: Efficacy of <i>B. diffusa</i> in HepG2 CDX model	148
Figure 4.28: Effect of <i>A. aspera</i> , <i>B. diffusa</i> and sorafenib on serum ALT level.....	151
Figure 4.29: Effect of <i>A. aspera</i> , <i>B. diffusa</i> and sorafenib on serum AST level.....	151
Figure 4.30: Effect of <i>A. aspera</i> , <i>B. diffusa</i> and sorafenib on serum ALP level.....	152
Figure 4.31: Effect of <i>A. aspera</i> , <i>B. diffusa</i> and sorafenib on serum creatinine level	152
Figure 4.32: Effect of <i>A. aspera</i> , <i>B. diffusa</i> and sorafenib on total bilirubin level.....	153
Figure 4.33: Effect of <i>A. aspera</i> , <i>B. diffusa</i> and sorafenib on tumor weight.....	154
Figure 4.34: Effect of <i>A. aspera</i> and sorafenib on percentage change in tumor volume on day 21.....	155
Figure 4.35: Effect of <i>B. diffusa</i> and sorafenib on percentage change in tumor volume on day 21.....	156
Figure 4.36: Effect of <i>A. aspera</i> , sorafenib and their combination on fold change of VEGF expression.....	157
Figure 4.37: Effect of <i>A. aspera</i> , sorafenib and their combination on VEGF expression	158
Figure 4.38: Effect of <i>A. aspera</i> , sorafenib and their combination on fold change in.....	158
Figure 4.39: Effect of <i>A. aspera</i> , sorafenib and their combination on p-ERK expression ...	159
Figure 4.40: Effect of <i>B.diffusa</i> extract and sorafenib on fold change in VEGF	159
Figure 4.41: <i>B.diffusa</i> , sorafenib and their combination effect on VEGF expression.....	160
Figure 4.42: Effect of <i>B.diffusa</i> extract and sorafenib on fold change of p-ERK/t-ERK ratio	160

Table of Contents

Figure 4.43: Effect of <i>B. diffusa</i> , sorafenib and their combination on p-ERK expression ...	161
Figure 4.44: Proliferation index of Ki67 by immunohistochemistry assay	162
Figure 4.45: Representative images of Ki67 staining by Immunohistochemistry assay	163
Figure 4.46: Mean Vascular density (MVD) of CD31 by immunohistochemistry assay	164
Figure 4.47: Representative images of MVD of CD31 by Immunohistochemistry assay	165
Figure 4.48: Schematic representation of anti-cancer activity of alcoholic <i>A. aspera</i> and <i>B. diffusa</i> extract	166
Figure 4.49: Graphical abstract.....	167

Table of Contents

List of Table

Table 2.1: HCC pathways, their role in disease progression and therapy.....	21
Table 2.2: HCC disease marker	28
Table 2.3: Summary of approved TKI and other drugs in HCC treatment.....	32
Table 2.4: Details of carcinogen inducing different type of cancers	37
Table 3.1: Mobile phase and elution program.....	56
Table 3.2: Docking protein with their PDB ID.....	57
Table 4.1: Organoleptic properties of <i>A. aspera</i> extracts.....	77
Table 4.2: Organoleptic properties of <i>B. diffusa</i> extracts.....	77
Table 4.3: Organoleptic properties of <i>E. littorale</i> extracts.....	77
Table 4.4: Heavy metals and microbial analysis of extracts	78
Table 4.5: Preliminary phytochemical screening of <i>A. aspera</i> (root) extract	79
Table 4.6: Preliminary phytochemical screening of <i>B. diffusa</i> (root) extract	80
Table 4.7: Preliminary phytochemical screening of <i>E. littorale</i> (whole plant) extract.....	81
Table 4.8: IC ₅₀ value of extracts and reference compound	85
Table 4.9: Percentage of cell population in different stages of cell death	90
Table 4.10: Compounds identified in alcoholic extract of <i>A. aspera</i> by LCMS	92
Table 4.11: Compounds identified in alcoholic extract of <i>B. diffusa</i> by LCMS	98
Table 4.12: Binding affinities between active components of <i>A. aspera</i> and target proteins	104
Table 4.13: Binding affinities between active components of <i>B. diffusa</i> and target proteins	105
Table 4.14: Docking of sorafenib on VEGF protein.....	107
Table 4.15: Docking of alcoholic extract of <i>B. diffusa</i> on VEGF protein.....	108
Table 4.16: Docking of alcoholic extract of <i>A. aspera</i> on VEGF protein	111
Table 4.17: Docking of sorafenib on p53 protein.....	114
Table 4.18: Docking of alcoholic extract of <i>B. diffusa</i> on p53 protein.....	115
Table 4.19: Docking of alcoholic extract of <i>A. aspera</i> on p53 protein.....	118

Table of Contents

Table 4.20: Docking of sorafenib on PI3K protein.....	121
Table 4.21: Docking of alcoholic extract of <i>B. diffusa</i> on PI3K protein	122
Table 4.22: Docking of alcoholic extract of <i>A. aspera</i> on PI3K protein	125
Table 4.23: Observations for the limit test for alcoholic extract of <i>A. aspera</i> in rats.....	128
Table 4.24: Observations for the limit test for alcoholic extract of <i>B. diffusa</i> in rats.....	129
Table 4.25: Observations for the limit test for alcoholic extract of <i>E. littorale</i> in rats.....	129
Table 4.26: Data of percentage change in body and liver weight, liver and spleen index on day 28	131
Table 4.27: Data of liver function parameters on day 28.....	131
Table 4.28: Data of percentage change in body weight, liver and spleen index	135
Table 4.29: Data of liver function parameters.....	136
Table 4.30: Growth rate of tumors in male and female mice	140
Table 4.31: Percentage tumor growth inhibition on day 21	142
Table 4.32: Body weight Data	146
Table 4.33: Data of percentage tumor growth inhibition on day 21	149
Table 4.34: Data of T/C ratio with tumor weight	150